KRRO
Korro Bio, Inc.·Healthcare
12.68
3.058%(−0.40)
Market ClosedLast Updated: — ET
52W L: $5.2052W H: $55.89
KRRO NEWS
globenewswire.com
17h ago
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
benzinga.com
Mar 13
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio reported a net loss of $117.3 million for the year ended December 31, 2025, compared to a loss of $83.6 million in the previous year, driven by non-cash impairment charges.
zacks.com
Mar 12
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Bio, Inc. (KRRO) came out with a quarterly loss of $5.32 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to a loss of $2.26 per share a year ago.
globenewswire.com
Mar 12
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy Advanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026 Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on December 31, 2025, and provided a corporate update.
globenewswire.com
Mar 9
Korro Announces Oversubscribed $85 Million Private Placement
CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced it has entered into a subscription agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $85 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about Tuesday, March 10, 2026, subject to satisfaction of customary closing conditions.
defenseworld.net
Mar 5
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts
Shares of Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) have received an average rating of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, three have given a buy recommendation and one has issued
